{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.7","upperLimit":"4.7","value":"4.3"},{"groupId":"OG001","lowerLimit":"2.0","upperLimit":"2.8","value":"2.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"337"},{"groupId":"OG001","value":"170"}],"units":"Participants"}],"description":"The ECOG performance status was used to evaluate participant's disease progression and the effect of the disease on the participant's activities of daily living. It ranges on the scale from 0-5 (0 = normal activity; 1= symptoms but ambulatory; 2= in bed for \\< 50% of the time; 3= in bed for \\> 50% of the time; 4= 100% bedridden; 5= dead). Time to definitive deterioration in ECOG performance status score from baseline was defined as a change from 0, 1 to \\>=2, or from 2 to \\>=3.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 35 mg/m\\^2 of TAS-102 tablets orally BID for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until a discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.","id":"OG000","title":"TAS-102+BSC"},{"description":"Participants received 35 mg/m\\^2 of matching placebo for TAS-102 tablets orally BID for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.","id":"OG001","title":"Placebo+BSC"}],"paramType":"MEDIAN","populationDescription":"Analysis was performed on the ITT population that included all randomized participants, regardless of whether or not study treatment was administered.","reportingStatus":"POSTED","timeFrame":"At the time of randomization (Day 1 Cycle 1) and within 24 hours prior to start of study treatment in every cycle (maximum duration: up to approximately 46 months)","title":"Time to Deterioration of European Cooperative Oncology Group (ECOG) Performance Status Score From Baseline","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"months"}